Please assess the completion status of the following clinical trial:

Trial Title: SR-BI and Antiviral Treatment Response in HCV

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Naive to IFN treatment and other experimental antiviral or immunosuppressive therapy before enrollment.~2. Serum alanine aminotransferase levels, at least, twice the upper limit of normal on two occasions within the previous 6 months.~Exclusion Criteria:~1. Positive for hepatitis B surface antigen~2. Positive for human immunodeficiency virus antibody~3. Had a known history or evidence of autoimmune liver disease, inheritable disorders, renal insufficiency, malignancy~4. Had a history of daily alcohol consumption greater than 20 gram or active drug abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HCV group (Peginterferon alfa-2a) (Type: None): A total of 156 chronic HCV genotype 1 or 2 patients who received Peginterferon alfa-2a (Peg-IFN alfa-2a) plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics.
- Control Group (Type: None): There were 153 healthy controls negative for anti-HCV enrolled simultaneously from the database of Health Management Center.

Based on this trial design, predict the completion outcome and termination type (if applicable).